TL;DR: The Centers for Medicare & Medicaid Services modified NCD 135, the national coverage determination governing vitamin B12 injections to strengthen tendons, ligaments, and related foot structures, effective March 7, 2026. The policy confirms these injections are not covered under Medicare. Here's what billing teams need to know.
This CMS vitamin B12 injection coverage policy has been on the books for years, but the March 7, 2026 modification makes it worth a fresh look. Under NCD 135 in the CMS Medicare system, vitamin B12 injections administered to strengthen tendons, ligaments, or other foot structures are explicitly excluded from Medicare coverage. No CPT or HCPCS codes are listed in the policy data—more on that below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Vitamin B12 Injections to Strengthen Tendons, Ligaments, etc., of the Foot |
| Policy Code | NCD 135 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium — high denial risk if billed without understanding both exclusion grounds |
| Specialties Affected | Podiatry, Orthopedics, Physical Medicine, Primary Care |
| Key Action | Do not bill Medicare for vitamin B12 injections used to treat or strengthen foot tendons or ligaments — claims will deny on two independent grounds |
CMS Vitamin B12 Injection Coverage Criteria and Medical Necessity Requirements 2026
The CMS vitamin B12 injection coverage policy under NCD 135 is one of the cleaner, more absolute policies you'll encounter. There are no tiers, no qualifying diagnoses, no prior authorization pathway that unlocks coverage. The determination is a flat non-coverage ruling.
CMS denies coverage on two separate grounds. First, there is no clinical evidence that vitamin B12 injections strengthen weakened tendons or ligaments. Second, this treatment falls under the subluxation exclusion as a nonsurgical treatment. Either ground alone would be enough to deny. Together, they make this one of the most airtight non-coverage positions in the NCD library.
The medical necessity standard here is §1862(a)(1) of the Social Security Act—the "reasonable and necessary" requirement. CMS has determined these injections do not meet that standard for this specific indication. That's not a judgment about vitamin B12 injections broadly. It's a judgment about this specific use case: injecting B12 to address structural weakness in foot tendons and ligaments.
If your providers are billing vitamin B12 injections for legitimate indications—pernicious anemia, B12 deficiency, neurological conditions—those claims go through a different coverage framework entirely. NCD 135 is narrowly scoped to the foot-strengthening indication. Don't let the broad language of a denial code confuse your team into thinking all B12 injections are at risk.
Whether vitamin B12 injections for foot tendons are covered under Medicare is a straightforward question: they are not. Prior authorization is not relevant here—there is no authorization pathway to pursue. The coverage policy closes the door completely.
CMS Vitamin B12 Injection Exclusions and Non-Covered Indications
The entire purpose of NCD 135 is to establish non-coverage. This isn't a policy with a covered tier and a non-covered tier—it's a policy that exists solely to exclude a specific service.
Ground one: lack of clinical evidence. CMS finds no evidence that vitamin B12 injections are effective for strengthening weakened tendons and ligaments in the foot. This is the medical necessity argument. Without evidence of clinical benefit, the service can't meet the reasonable and necessary standard.
Ground two: the subluxation exclusion. This is the less obvious ground, and it's worth understanding. Medicare excludes coverage for nonsurgical treatment related to subluxation of the foot. This injection falls into that exclusion category. Even if someone argued there was clinical merit to the treatment, the subluxation exclusion would still block reimbursement under Medicare.
The real issue here is that these two grounds operate independently. If a provider or patient appeals on the basis that new evidence supports B12 injections for this purpose, the subluxation exclusion still applies. You'd need to defeat both arguments to get coverage. That's an extremely high bar—effectively insurmountable under current policy.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Vitamin B12 injection to strengthen foot tendons or ligaments | Not Covered | No specific codes listed in policy | Denied under §1862(a)(1); dual exclusion grounds apply |
| Vitamin B12 injection for subluxation-related nonsurgical treatment of the foot | Not Covered | No specific codes listed in policy | Falls under Medicare subluxation exclusion regardless of clinical arguments |
Note: The policy does not list specific CPT or HCPCS codes. See the Affected Codes section below for details.
CMS Vitamin B12 Injection Billing Guidelines and Action Items 2026
These action items apply as of the effective date of March 7, 2026. If you're in podiatry, orthopedics, physical medicine, or a primary care practice with high Medicare volume, run through this list before the end of the month.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for vitamin B12 injection claims billed to Medicare. Pull claims from the last 12 months where the indication involved tendon or ligament strengthening in the foot. If any of those went to Medicare, you have exposure. Review them now. |
| 2 | Update your superbill or charge capture tool to flag B12 injection claims for Medicare patients when the indication is musculoskeletal foot treatment. The claim denial will come—but catching it pre-submission is far cheaper than working a denial. |
| 3 | Educate your providers on the dual exclusion. It's not enough to know these claims are denied. Providers need to understand why—so they don't waste time building medical necessity documentation for a service with two independent grounds for non-coverage. Documentation won't save these claims. |
| 4 | Check your Medicare Administrative Contractor (MAC) for any local coverage determination (LCD) that might intersect with this NCD. NCDs set the national floor. Some MACs have issued LCDs that add context or address related codes. NCD 135 is clear, but knowing your MAC's position on related B12 billing guidelines is good practice. |
| 5 | Review the Medicare Benefit Policy Manual cross-references. CMS points to Chapter 1, §30 and Chapter 16, §100 of the Medicare Benefit Policy Manual. If your compliance officer or billing consultant isn't familiar with those sections, cross-reference them now. Chapter 16 covers exclusions from coverage, which is directly relevant to the subluxation exclusion analysis. |
| 6 | Do not attempt prior authorization as a workaround. There is no prior authorization pathway for this service under Medicare. Pursuing prior auth wastes time and creates a paper trail that doesn't help you. |
| 7 | For patients who want this treatment, document the financial waiver properly. If a Medicare patient requests vitamin B12 injections for this purpose and understands Medicare won't cover it, use an Advance Beneficiary Notice of Noncoverage (ABN). This protects the practice and sets clear patient expectations on out-of-pocket costs. |
If your practice has significant exposure here or you're unsure how to categorize historical claims, talk to your compliance officer before making retroactive corrections. Voluntary disclosure has specific protocols, and you don't want to self-report incorrectly.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vitamin B12 Injections Under NCD 135
Covered CPT Codes
The policy does not list any covered codes. There are no covered indications under NCD 135 for vitamin B12 injections to strengthen foot tendons, ligaments, or related structures.
Not Covered Codes
NCD 135 lists no specific CPT codes, no HCPCS codes, and no ICD-10-CM diagnosis codes. The non-coverage is explicit in the policy language and is indication-based—meaning the exclusion applies based on the clinical purpose of the injection, not a specific code match.
This is by design. The policy is scoped tightly to a specific use case. Your MAC and your internal coding resources are the right place to identify which codes apply to your claims in practice. If you're unsure how to code these encounters or map provider documentation to the right codes, loop in a billing consultant before the next claim cycle.
Check your remittance advice for denial codes referencing NCD 135 or §1862(a)(1). That's your signal that this policy is in play.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.